Wockhardt Ltd (WOCKPHARMA)
·Next Day Close·-3.49%·₹2,187.2
Key EventTrading window closure announced ahead of Q2 results
Wockhardt Limited (WOCKPHARMA)
·Next Day Close·-1.33%·₹1,906.8
Key EventBoard approved unaudited financial results for Q1 FY2026 and confirmed limited review by auditors.
ImpactInvestors should note that the company has disclosed Q1 FY2026 financials with no material misstatements, but diluted EPS remains negative in consolidated results.Sign up to read impact
Wockhardt Limited (WOCKPHARMA)
·Next Day Close·-1.33%·₹1,906.8
Key EventMonitoring Agency Report confirms QIP proceeds utilization compliance
ImpactInvestors can view this as a positive compliance signal with no operational or financial deviations reported.Sign up to read impact
Wockhardt Limited (WOCKPHARMA)
·Next Day Close·-1.33%·₹1,906.8
Key EventWockhardt AGM approves ₹3,000 Crore capital raise and related party transactions
ImpactShareholders backed capital expansion and related party deals with strong approval rates.Sign up to read impact
Wockhardt Limited (WOCKPHARMA)
·Next Day Close·-1.33%·₹1,906.8
Key EventWockhardt reports Q1 FY27 results showing PAT of Rs.107 crores and 26% revenue growth
ImpactThe company is showing strong recovery with profitable growth and expanding international biotech operations.Sign up to read impact
Wockhardt Limited (WOCKPHARMA)
·Next Day Close·-2.13%·₹1,973
Key EventAGM time revised to 10:30 a.m. IST on August 10, 2026
ImpactShareholders must attend the revised AGM timing and note the new transparency detail on related party approvals.Sign up to read impact
Wockhardt Limited (WOCKPHARMA)
·Next Day Close·+2.53%·₹1,857.35
Wockhardt Limited received a SEBI-mandated share transfer agent certificate for the quarter ended June 30, 2026, confirming dematerialized securities were processed and updated in depositories. The filing acknowledges receipt of the certificate from MUFG Intime India Private Limited, the company's registrar and share transfer agent.
Sign up to read summaryWockhardt Ltd (WOCKPHARMA)
·Next Day Close·+0.99%·₹1,961.25
Key EventWockhardt's Zaynich receives US FDA approval as first India-developed antibiotic, signaling entry into global novel antibiotic market.
ImpactWockhardt is transitioning from financial stabilization to scalable growth driven by Zaynich's global launch and biosimilar expansion, with profitability now embedded in its core model.Sign up to read impact
Wockhardt Limited (WOCKPHARMA)
·Next Day Close·-0.74%·₹1,949.05
Wockhardt Limited announced that its trading window for equity shares will close on 1 July 2026 and remain shut for 48 hours following the release of unaudited quarterly results for the quarter ended 30 June 2026, with the board meeting date to be disclosed later.
Sign up to read summaryWockhardt Limited (WOCKPHARMA)
·Next Day Close·+0.41%·₹1,934.95
Wockhardt announced its US launch strategy for Zaynich, a novel antibiotic targeting carbapenem-resistant infections with 96.8% cure rates, backed by strong clinical data and a $1.5-2 billion global revenue potential. Management emphasized pricing at $1,200-$1,500/day, 75-80% discounts in India, and a 'hockey stick' growth trajectory after 12-18 months, supported by in-house US commercial capabilities and partnerships. The filing highlights strategic focus on high-margin antibiotic innovation, PLI scheme benefits, and exiting unprofitable US generics to fund R&D, positioning Wockhardt as a leader in next-generation antibiotics amid rising resistance threats.
Sign up to read summary